Jasper Therapeutics, Inc.
JSPRW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Other share classesJSPR
Q1 2023 vs. Q4 2022
How the institutions holding Jasper Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 15 | 11 | −4 |
| Shares | 1.31M | 2.03M | +718.7K (+54.8%) |
| Value | $55.5K | $430.9K | +$375.5K (+676.9%) |
New holders (1)
Institutions that held Jasper Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CSS LLC | 81,957 | $16.4K | 0.00% |
Sold out (5)
Institutions that held Jasper Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Owl Creek Asset Management, L.P. | 267,189 | $8.02K |
| Privium Fund Management B.V. | 98,202 | $3.33K |
| Shaolin Capital Management LLC | 20,420 | $1.00K |
| Wolverine Asset Management LLC | 10,646 | $319 |
| HRT Financial LP | 22,524 | $0 |